Oral Semaglutide OASIS 4 Sub-Analysis: 21.6% Weight Loss

Oral semaglutide 25 mg is a once-daily pill developed for chronic weight management.

At the European Congress on Obesity (ECO 2026), researchers presented exciting sub-analyses from the Phase 3 OASIS 4 trial, highlighting the efficacy of a daily 25 mg oral formulation of semaglutide. The data showed that a subset of patients classified as "early responders" achieved an average body weight reduction of 21.6% after 64 weeks of treatment. Additionally, the daily pill led to significant improvements in physical function and mobility, particularly for patients starting with compromised physical capacity.

These findings come as daily oral GLP-1 pills gain popularity as alternatives to weekly subcutaneous injections. For patients seeking needle-free options, understanding how quickly these oral treatments work and how they improve daily function is highly valuable. This article breaks down the key results from the OASIS 4 sub-analyses.

Understanding the Methodology of the OASIS 4 Clinical Trial

The OASIS 4 study (NCT05564117) was a Phase 3 randomized, double-blind, placebo-controlled, multi-center trial. It evaluated the efficacy, safety, and tolerability of once-daily oral semaglutide 25 mg in 307 adults living with obesity or overweight and related comorbidities. To avoid confounding variables, patients with type 2 diabetes were excluded from this cohort.

Participants were randomized in a 2:1 ratio to receive either the daily 25 mg tablet or a placebo, alongside standard dietary and lifestyle counseling. The 71-week study included a 12-week dose-escalation phase to help prevent stomach side effects, followed by a 52-week maintenance period. The primary endpoint was percentage weight change at week 64, where the treatment group averaged a 13.6% weight loss compared to 2.2% for the placebo group.

Analyzing the Early Responder Phenotype and Weight Loss Trajectories

The sub-analysis presented at ECO 2026 focused on identifying "early responders," defined as patients who lost 10% or more of their body weight by week 16. Approximately 28.8% of participants in the treatment group met this early responder definition. These early responders achieved an average 13.2% weight loss by week 16, which rose to a remarkable 21.6% weight loss by week 64.

This level of weight loss is comparable to results seen with high-dose weekly injections or bariatric surgery. Meanwhile, patients who did not meet the early responder threshold still achieved a meaningful 11.5% weight loss by week 64. Because a 5% to 10% weight reduction is known to improve health markers like blood pressure and cholesterol, both groups achieved substantial clinical benefits, proving that continuing the daily regimen is highly worthwhile.

Quantifying Physical Function and Mobility Enhancements

Weight care is not just about numbers on a scale; the impact on a patient's physical mobility is equally important. A secondary sub-analysis evaluated changes in physical function using the IWQOL-Lite-CT questionnaire, a validated tool that measures the impact of weight on daily life. Investigators focused on patients who entered the trial with poor physical function.

Among this group, 77.3% of patients treated with oral semaglutide 25 mg achieved clinically meaningful improvements in their mobility scores by week 64, compared to 42.9% in the placebo group. The oral semaglutide group experienced nearly a double increase in physical capacity, reporting significant improvements in daily activities such as:

• Walking moderate distances without joint pain or shortness of breath.
• Bending over easily to tie shoes or pick up items from the floor.
• Climbing stairs comfortably.
• Standing for longer periods during daily tasks.
• Sustaining physical stamina during recreational activities.

Comparing Oral Semaglutide with Injectable GLP-1 Alternatives

The introduction of a highly effective daily pill marks a major change in obesity care. Historically, GLP-1 receptor agonists have required weekly subcutaneous injections. While injections remain popular, research shows that many patients prefer a daily pill due to needle anxiety or travel convenience. For patients evaluating options, comparing semaglutide treatment programs and tirzepatide options is a key first step.

The OASIS 4 data shows that oral semaglutide 25 mg delivers weight loss results that compete directly with weekly injections. For example, weekly injections of Wegovy 2.4 mg show an average weight loss of 14.9% over 68 weeks, which is very close to the 13.6% average and 21.6% early responder results seen with the oral tablet. However, the oral pill requires strict compliance with morning rules: it must be taken on an empty stomach with a small sip of water, and patients must wait 30 minutes before eating or drinking.

Clinical Safety, Tolerability, and the Path to Personalized Weight Management

Oral semaglutide 25 mg showed a safety profile consistent with the GLP-1 class, with mild to moderate gastrointestinal side effects like nausea, diarrhea, and constipation being the most common. These side effects occurred primarily during the 12-week titration phase as patients' bodies adjusted to the drug. Discontinuation rates due to side effects were low and similar to those of injectable GLP-1s.

The ability to identify early responders at week 16 gives doctors a valuable tool to personalize metabolic care. By tracking progress early, clinicians can decide whether to maintain the current dose, adjust lifestyle support, or explore other therapeutic avenues. To explore your options, you can check if you qualify online and view current pricing for personalized metabolic programs. Consulting with a licensed healthcare professional is the best way to choose the right delivery method for your lifestyle.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.